Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Lemonade Inc (LMND) Price & Performance

ADMA Biologics IncTrade
Lemonade IncTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Lemonade Inc — how do they compare? ADMA Biologics Inc trades at $9.93 (market cap $2.22B), while Lemonade Inc trades at $51.55 (market cap $4.09B). The key difference: Lemonade Inc is the larger of the two by market cap. Which is the better fit depends on your goals.

ADMALMND
Market Cap
$2.22B$4.09B
Sector
HealthFinancials
52-Week High
$20.38$96.57
52-Week Low
$7.60$47.38
Enterprise Value
$2.29B$3.95B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.

The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.

Lemonade Inc

Lemonade (LMND) trades at $52.68, down 0.49% on the day, with technical indicators showing a bearish bias. The company reported Q2 2026 revenue growth of 79% year-over-year and has beaten EPS estimates for three consecutive quarters, yet remains unprofitable with a net income margin of -22.43% in 2025. Recent news highlights management's presentation at an Oppenheimer conference and ongoing expansion of renters insurance products.

The outlook is mixed; accelerating premium growth and a path to positive adjusted EBITDA by Q4 2026 offer upside potential, but high valuation multiples, persistent losses, and bearish technical signals present significant risks. Analyst consensus is evenly split, reflecting uncertainty around the profitability timeline.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Lemonade Inc

Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.

Read more on LMND